164 related articles for article (PubMed ID: 29489901)
1. Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas.
Michaud K; de Tayrac M; D'Astous M; Paquet C; Gould PV; Saikali S
PLoS One; 2018; 13(2):e0193213. PubMed ID: 29489901
[TBL] [Abstract][Full Text] [Related]
2. Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.
Michaud K; de Tayrac M; D'Astous M; Duval C; Paquet C; Samassekou O; Gould PV; Saikali S
PLoS One; 2016; 11(12):e0168728. PubMed ID: 28030632
[TBL] [Abstract][Full Text] [Related]
3. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
Miettinen H; Kononen J; Sallinen P; Alho H; Helen P; Helin H; Kalimo H; Paljärvi L; Isola J; Haapasalo H
J Neurooncol; 1999 Feb; 41(3):205-11. PubMed ID: 10359140
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
Jeon YK; Park K; Park CK; Paek SH; Jung HW; Park SH
Neuropathology; 2007 Feb; 27(1):10-20. PubMed ID: 17319279
[TBL] [Abstract][Full Text] [Related]
5. Expression of cyclin A and topoisomerase IIalpha of oligodendrogliomas is correlated with tumour grade, MIB-1 labelling index and survival.
Park SH; Suh YL
Histopathology; 2003 Apr; 42(4):395-402. PubMed ID: 12653952
[TBL] [Abstract][Full Text] [Related]
6. Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma.
Deininger MH; Weller M; Streffer J; Meyermann R
Cancer; 1999 Nov; 86(9):1832-9. PubMed ID: 10547558
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas.
Bortolotto S; Chiadò-Piat L; Cavalla P; Bosone I; Chiò A; Mauro A; Schiffer D
Int J Cancer; 2000 Nov; 88(4):554-7. PubMed ID: 11058870
[TBL] [Abstract][Full Text] [Related]
8. Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas.
Godfraind C; Rousseau E; Ruchoux MM; Scaravilli F; Vikkula M
Neuropathol Appl Neurobiol; 2003 Oct; 29(5):462-71. PubMed ID: 14507338
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas.
Watanabe T; Nakamura M; Yonekawa Y; Kleihues P; Ohgaki H
Acta Neuropathol; 2001 Mar; 101(3):185-9. PubMed ID: 11307615
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.
Namazie A; Alavi S; Olopade OI; Pauletti G; Aghamohammadi N; Aghamohammadi M; Gornbein JA; Calcaterra TC; Slamon DJ; Wang MB; Srivatsan ES
Laryngoscope; 2002 Mar; 112(3):472-81. PubMed ID: 12148857
[TBL] [Abstract][Full Text] [Related]
11. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
[TBL] [Abstract][Full Text] [Related]
12. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas.
Fallon KB; Palmer CA; Roth KA; Nabors LB; Wang W; Carpenter M; Banerjee R; Forsyth P; Rich K; Perry A
J Neuropathol Exp Neurol; 2004 Apr; 63(4):314-22. PubMed ID: 15099021
[TBL] [Abstract][Full Text] [Related]
14. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M
Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848
[TBL] [Abstract][Full Text] [Related]
15. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
Iwadate Y; Matsutani T; Hara A; Hirono S; Ikegami S; Kobayashi M; Ito D; Kawauchi D; Horiguchi K; Tamiya A; Higuchi Y
J Neurooncol; 2019 Jan; 141(1):205-211. PubMed ID: 30565028
[TBL] [Abstract][Full Text] [Related]
16. Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
Dehais C; Laigle-Donadey F; Marie Y; Kujas M; Lejeune J; Benouaich-Amiel A; Pedretti M; Polivka M; Xuan KH; Thillet J; Delattre JY; Sanson M
Cancer; 2006 Oct; 107(8):1891-7. PubMed ID: 16986124
[TBL] [Abstract][Full Text] [Related]
17. [Influence of molecular-genetic factors on prognosis in patients with oligodendroglial tumors].
Absaliamova OV; Korshunov AG; Loshakov VA; Kobiakov GL; Golanov AV; Urakov SV; Amanov RD; Lichinitser MR
Zh Vopr Neirokhir Im N N Burdenko; 2009; (1):17-23; discussion 23-4. PubMed ID: 19507310
[TBL] [Abstract][Full Text] [Related]
18. Deletion of chromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 and p15/MTS2 gene protein in hepatocellular carcinomas.
Shao J; Li Y; Li H; Wu Q; Hou J; Liew C
Chin Med J (Engl); 2000 Sep; 113(9):817-22. PubMed ID: 11776078
[TBL] [Abstract][Full Text] [Related]
19. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
[TBL] [Abstract][Full Text] [Related]
20. Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas.
Pohl U; Cairncross JG; Louis DN
Brain Pathol; 1999 Oct; 9(4):639-43. PubMed ID: 10517502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
